Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711001 | 0.97 | HTR2A (0.38) | HTR2AHRH1MAPTCHRM1CHRM3 | |
| SCHEMBL15710764 | 0.84 | HTR2A (0.43) | HTR2AHRH1NOS3NOS1NOS2 | |
| SCHEMBL15711311 | 0.82 | HTR2A (0.42) | HTR2AHRH1NOS3NOS1NOS2 | |
| SCHEMBL17359140 | 0.82 | ALDH1A1 (0.46) | HTR2AHRH1ALDH1A1TSHRKDM4A | |
| SCHEMBL28027517 | 0.80 | ALDH1A1 (0.43) | HTR2AHRH1ALDH1A1TSHRKDM4A | |
| SCHEMBL3129317 | 0.79 | TET2 (0.48) | HTR2AHRH1MAPTCHRM1CHRM3 | |
| SCHEMBL1672355 | 0.79 | GABRR1 (0.52) | HTR2AHRH1HDAC1HDAC2ENPEP | |
| SCHEMBL847328 | 0.79 | GABRR1 (0.52) | HTR2AHRH1HDAC1HDAC2ENPEP | |
| SCHEMBL15711004 | 0.77 | CYP3A4 (0.39) | HTR2AHRH1MAPTCHRM1CHRM3 | |
| SCHEMBL1527366 | 0.77 | NOS2 (0.53) | NOS3NOS1NOS2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740738-B1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) | 2018-03-28 | — | — | EP | claimed |
| EP-2740738-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | Beijing FSwelcome Technology Development Co., Ltd. (CN) | 2014-06-11 | — | — | EP | claimed |
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2014-05-22 | — | — | US | claimed |
| EP-0050762-B1 | PROCESS FOR THE PREPARATION OF VINYLCYCLOPROPANE DERIVATIVES | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1984-06-13 | — | — | EP | claimed |
| US-12606823-B2 | Modified CPF1 guide RNA | Breeze Bio, Inc. | 2026-04-21 | — | — | US | disclosed |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| EP-3757090-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2024-06-12 | — | — | EP | disclosed |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-08 | — | — | US | disclosed |
| EP-4241767-A2 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-01 | — | — | US | disclosed |
| EP-3757090-A9 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2023-07-19 | — | — | EP | disclosed |
| US-20220023427-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-01-27 | — | — | US | disclosed |
| US-5861428-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, INFLAMMATION, OSTEOPENIAS, TEMPERO | BAYER CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5861427-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, CONDITIONS LEADING TO INFLAMMATORY | BAYER HEALTHCARE LLC | 1999-01-19 | — | — | US | disclosed |
| US-5859047-A | ANTIARTHRITIC AGENTS, NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854277-A | Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0050762-A1 | Process for the preparation of vinylcyclopropane derivatives | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | PCNA, POLI, MKI67 | HTR2A 4425/4885HRH1 1880/4885MAPT 2475/4885 |
| US-12606823-B2 | Modified CPF1 guide RNA | CPSF1, CPSF6, UPF1 | HTR2A 3506/4885HRH1 4359/4885MAPT 3342/4885 |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | HTR2A 2317/4885HRH1 1737/4885MAPT 2962/4885 |
| US-20220023427-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS2, APOB, PHOSPHO1 | HTR2A 1476/4885HRH1 2742/4885MAPT 4186/4885 |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | SGMS2, APOB, PHOSPHO1 | HTR2A 1476/4885HRH1 2742/4885MAPT 4186/4885 |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, MBOAT1, SGMS1 | HTR2A 2317/4885HRH1 1737/4885MAPT 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.